FDA Opens Useful Dialogue on Orange Book Patent Listings
"In a notice published in the Federal Register on June 1 concerning the establishment of a public docket via patent information listing in the Orange Book, the US Food and Drug Administration has asked for public comment on the long-standing question as to what types of pharmaceutical patents should be listed in the FDA's Orange Book and 'the impact that any change to current patent listing practices may have on drug product development.'"
Related contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.